Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Inclusion Criteria: * Histologically confirmed solid tumor, including, but not limited to, the following: * Prostate * Breast * Ovary * Colon * Kidney * Head and neck * Stomach * Melanoma * Metastatic or unresectable disease * No standard curative or palliative therapy exists or is no longer effective * Progressive disease as indicated by the following: * Non-prostate cancer * New lesions or increase in pre-existing lesions on bone scintigraphy, CT scan, MRI, or by physical examination * No increase in biochemical markers (e.g., carcinoembryonic antigen or CA-15-3) or symptoms as sole evidence of disease progression * Prostate cancer * Must have castrate metastatic disease (i.e., disease progression after castration or treatment with a gonadotropin-releasing hormone \[GnRH\] analog) * Patients who have not undergone surgical orchiectomy must continue with medical therapy (i.e., GnRH analogs) to maintain castrate levels of serum testosterone \< 50 ng/dL * Patients who received an antiandrogen as part of first-line hormonal therapy must show disease progression after discontinuing treatment * Progressive metastatic disease on imaging studies (e.g., bone scan, CT scan, or MRI) OR metastatic disease and a rising prostate-specific antigen (PSA) allowed * Biochemical progression is defined as a minimum of 3 rising PSA values from baseline obtained at least 1 week apart OR 2 rising PSA values obtained more than 1 month apa…